Mylan Loses Bid to Exit EpiPen Price Case as Pfizer Gets Win (1)

Mylan NV must face antitrust litigation brought by drug distributors who claim the company schemed to delay generic versions of its EpiPen, but Pfizer Inc. affiliates that manufacture the lifesaving allergy injection are off the hook, a federal judge in Kansas ruled.

Judge Daniel D. Crabtree let part of the case move forward, citing allegations that Mylan “traded” a settlement of patent claims over Teva Pharmaceuticals Industries Ltd.'s proposed EpiPen generic for one resolving an unrelated case involving one of Teva’s drugs.

Crabtree, writing for the US District Court for the District of Kansas, said it’s plausible that the patent ...